Agile Therapeutics EBITDA 2013-2023 | AGRX
Agile Therapeutics ebitda from 2013 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Agile Therapeutics Annual EBITDA (Millions of US $) |
2022 |
$-49 |
2021 |
$-67 |
2020 |
$-47 |
2019 |
$-19 |
2018 |
$-20 |
2017 |
$-27 |
2016 |
$-30 |
2015 |
$-33 |
2014 |
$-19 |
2013 |
$-13 |
2012 |
$-23 |
Agile Therapeutics Quarterly EBITDA (Millions of US $) |
2023-09-30 |
$-4 |
2023-06-30 |
$-5 |
2023-03-31 |
$-6 |
2022-12-31 |
$-6 |
2022-09-30 |
$-18 |
2022-06-30 |
$-10 |
2022-03-31 |
$-15 |
2021-12-31 |
$-21 |
2021-09-30 |
$-14 |
2021-06-30 |
$-16 |
2021-03-31 |
$-16 |
2020-12-31 |
$-16 |
2020-09-30 |
$-15 |
2020-06-30 |
$-10 |
2020-03-31 |
$-8 |
2019-12-31 |
$-6 |
2019-09-30 |
$-4 |
2019-06-30 |
$-4 |
2019-03-31 |
$-5 |
2018-12-31 |
$-4 |
2018-09-30 |
$-4 |
2018-06-30 |
$-5 |
2018-03-31 |
$-7 |
2017-12-31 |
$-6 |
2017-09-30 |
$-7 |
2017-06-30 |
$-7 |
2017-03-31 |
$-7 |
2016-12-31 |
$-8 |
2016-09-30 |
$-7 |
2016-06-30 |
$-8 |
2016-03-31 |
$-7 |
2015-12-31 |
$-9 |
2015-09-30 |
$-9 |
2015-06-30 |
$-8 |
2015-03-31 |
$-7 |
2014-12-31 |
$-7 |
2014-09-30 |
$-6 |
2014-06-30 |
$-3 |
2014-03-31 |
$-2 |
2013-12-31 |
|
2013-09-30 |
$-3 |
2013-06-30 |
$-3 |
2012-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$0.001B |
$0.011B |
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
|